Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedNov 19, 2025
DataAggregated Company Financials
Companies177
  • 7D0.2%
  • 3M-0.4%
  • 1Y-0.2%
  • YTD-5.9%

In the last week, the Pharma industry is up 1.1%, with Sun Pharmaceutical Industries up 3.0%. Meanwhile, Cohance Lifesciences actually underperformed within the industry, shrinking 16% in the last week. The industry has been flat over the past 12 months despite the gain this week. Earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 20 Nov 2025₹20.4t₹4.2t₹611.1b30x33.4x4.9x
Sat, 18 Oct 2025₹20.3t₹4.1t₹589.5b30.6x34.4x5x
Mon, 15 Sep 2025₹20.6t₹4.1t₹589.1b31.5x35x5.1x
Wed, 13 Aug 2025₹20.0t₹4.1t₹592.4b31.2x33.8x4.9x
Fri, 11 Jul 2025₹20.4t₹4.0t₹594.1b32.6x34.3x5.1x
Sun, 08 Jun 2025₹20.2t₹4.0t₹595.3b32x33.9x5.1x
Tue, 06 May 2025₹19.7t₹3.9t₹563.0b29.8x35x5.1x
Thu, 03 Apr 2025₹19.2t₹3.9t₹559.4b29.5x34.4x4.9x
Sat, 01 Mar 2025₹18.0t₹3.9t₹561.5b25.8x32.1x4.6x
Mon, 27 Jan 2025₹19.9t₹3.8t₹531.6b31.6x37.5x5.2x
Wed, 25 Dec 2024₹20.8t₹3.8t₹526.7b34.8x39.4x5.5x
Fri, 22 Nov 2024₹20.1t₹3.8t₹526.7b31.6x38.1x5.3x
Sun, 20 Oct 2024₹21.4t₹3.7t₹492.6b40.1x43.4x5.7x
Tue, 17 Sep 2024₹21.7t₹3.7t₹492.6b42.6x44.1x5.8x
Thu, 15 Aug 2024₹20.2t₹3.8t₹489.0b35x41.4x5.4x
Sat, 13 Jul 2024₹18.6t₹3.6t₹449.9b35x41.4x5.2x
Mon, 10 Jun 2024₹17.4t₹3.6t₹448.1b32.7x38.8x4.9x
Wed, 08 May 2024₹16.9t₹3.5t₹420.1b34.3x40.1x4.8x
Fri, 05 Apr 2024₹17.1t₹3.5t₹418.9b33.5x40.9x4.9x
Sun, 03 Mar 2024₹16.9t₹3.5t₹418.7b33.2x40.4x4.9x
Tue, 30 Jan 2024₹15.9t₹3.4t₹396.1b34.8x40.2x4.7x
Thu, 28 Dec 2023₹14.8t₹3.4t₹395.2b32.8x37.5x4.4x
Sat, 25 Nov 2023₹14.0t₹3.4t₹395.1b31x35.6x4.2x
Mon, 23 Oct 2023₹13.1t₹3.3t₹368.0b29.8x35.6x4x
Wed, 20 Sep 2023₹13.3t₹3.3t₹369.5b30.3x35.9x4.1x
Fri, 18 Aug 2023₹13.1t₹3.3t₹367.0b28.7x35.6x4x
Sun, 16 Jul 2023₹11.9t₹3.2t₹342.6b26.3x34.9x3.8x
Tue, 13 Jun 2023₹11.0t₹3.2t₹342.4b25.8x32.1x3.5x
Thu, 11 May 2023₹10.6t₹3.1t₹297.8b27.2x35.5x3.4x
Sat, 08 Apr 2023₹9.8t₹3.0t₹277.5b24.5x35.2x3.3x
Mon, 06 Mar 2023₹9.4t₹3.0t₹277.5b23x33.9x3.1x
Wed, 01 Feb 2023₹9.7t₹2.9t₹284.5b25.5x34.1x3.3x
Fri, 30 Dec 2022₹9.9t₹2.9t₹274.9b26.7x36x3.5x
Sun, 27 Nov 2022₹10.1t₹2.9t₹274.9b26.9x36.8x3.5x
Price to Earnings Ratio

36.8x


Total Market Cap: ₹10.1tTotal Earnings: ₹274.9bTotal Revenue: ₹2.9tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.8x202320242025
Current Industry PE
  • Investors are pessimistic on the Indian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 33.4x which is lower than its 3-year average PE of 36.8x.
  • The industry is trading close to its 3-year average PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 31% per year over the last three years.
  • Revenues for these companies have grown 14% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market0.087%
Healthcare-0.011%
Pharma0.23%
Pharma0.23%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SUNPHARMA Sun Pharmaceutical Industries₹1.78k3.0%
+₹124.8b		0.4%PE41x
AUROPHARMA Aurobindo Pharma₹1.24k4.4%
+₹30.3b		-1.1%PE21x
IPCALAB Ipca Laboratories₹1.45k7.9%
+₹27.0b		-8.1%PE44.1x
AETHER Aether Industries₹888.1519.4%
+₹19.2b		7.3%PE60.5x
500124 Dr. Reddy's Laboratories₹1.25k1.7%
+₹17.4b		3.0%PE17.8x

Latest News

CIPLA
₹1,526.80
Cipla
7D
0.5%
1Y
3.8%

Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?

Nov 20
Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?
COHANCE
₹582.25
Cohance Lifesciences
7D
-15.6%
1Y
-54.5%

Cohance Lifesciences' (NSE:COHANCE) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 20
Cohance Lifesciences' (NSE:COHANCE) Sluggish Earnings Might Be Just The Beginning Of Its Problems
530549
₹361.80
Shilpa Medicare
7D
-9.5%
1Y
-17.8%

530549: Successful Phase 3 Results Will Drive Stronger Outlook Ahead

Analysts have raised their price target for Shilpa Medicare to ₹514.5. This update is supported by improved growth and profitability projections, which offset a slightly higher discount rate and lower expected future P/E. What's in the News Shilpa Medicare successfully completed its fourth complex clinical program, SMLINJ011, achieving positive topline Phase 3 results for OERIS™ (Ondansetron Extended-Release Injection).
RUBICON
₹695.05
Rubicon Research
7D
10.8%
1Y
n/a
AETHER
₹888.15
Aether Industries
7D
19.4%
1Y
7.3%

We Ran A Stock Scan For Earnings Growth And Aether Industries (NSE:AETHER) Passed With Ease

Nov 15
We Ran A Stock Scan For Earnings Growth And Aether Industries (NSE:AETHER) Passed With Ease
IPCALAB
₹1,447.40
Ipca Laboratories
7D
7.9%
1Y
-8.1%
EMCURE
₹1,370.10
Emcure Pharmaceuticals
7D
2.4%
1Y
4.9%

Emcure Pharmaceuticals Limited (NSE:EMCURE) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Nov 14
Emcure Pharmaceuticals Limited (NSE:EMCURE) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
506943
₹1,752.90
J. B. Chemicals & Pharmaceuticals
7D
-3.6%
1Y
5.2%
500420
₹3,729.85
Torrent Pharmaceuticals
7D
-2.4%
1Y
20.5%

500420: New Settlement Agreement Will Shape U S Market Opportunity After 2030

Analysts have raised their price target for Torrent Pharmaceuticals from ₹3,929 to ₹4,010, citing slightly improved revenue growth forecasts and higher projected profit margins. What's in the News Torrent Pharmaceuticals has entered into a settlement agreement with Eisai Co., Ltd.
ZYDUSLIFE
₹930.20
Zydus Lifesciences
7D
-2.2%
1Y
-1.8%

Analysts Are Updating Their Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Estimates After Its Second-Quarter Results

Nov 09
Analysts Are Updating Their Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Estimates After Its Second-Quarter Results
GLAND
₹1,769.80
Gland Pharma
7D
-3.7%
1Y
-0.7%

GLAND: Revenue Opportunities And Competitive Risks Will Be Balanced Going Forward

Narrative Update: Gland Pharma Price Target Revision Analysts have slightly lowered their price target for Gland Pharma from ₹1,938 to ₹1,925. This reflects modestly tempered expectations on revenue growth, profitability, and valuation multiples.
MANKIND
₹2,223.10
Mankind Pharma
7D
-2.1%
1Y
-13.6%

MANKIND: Expansion Into Russia And Rising Margins Will Drive Upside

Analysts have revised the fair value estimate for Mankind Pharma down from ₹2,799.65 to ₹2,725.59. This revision reflects slightly lower revenue growth expectations, partially offset by stronger profit margins and a marginally higher discount rate.
PPLPHARMA
₹188.80
Piramal Pharma
7D
-3.5%
1Y
-24.7%

PPLPHARMA: New Partnerships Will Drive Future Sector Expansion

Analysts have revised Piramal Pharma's fair value estimate down from ₹258.67 to ₹244.33 per share. This change reflects updated assumptions about revenue growth and profit margins.
SUNPHARMA
₹1,784.10
Sun Pharmaceutical Industries
7D
3.0%
1Y
0.4%

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Could Easily Take On More Debt

Nov 07
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Could Easily Take On More Debt
AUROPHARMA
₹1,235.80
Aurobindo Pharma
7D
4.4%
1Y
-1.1%
500124
₹1,250.10
Dr. Reddy's Laboratories
7D
1.7%
1Y
3.0%

Biosimilar Expansion And Legal Agreements Will Shape Future Market Opportunities

Analysts have revised their price target for Dr. Reddy's Laboratories upward from ₹1,287.37 to ₹1,300.62. This reflects renewed confidence driven by improved profit margin forecasts, despite marginally lower revenue growth expectations.